logo
#

Latest news with #RocheHoldingAG

Roche to Test Whether New Drug Can Prevent Alzheimer's Disease
Roche to Test Whether New Drug Can Prevent Alzheimer's Disease

Bloomberg

time2 days ago

  • Health
  • Bloomberg

Roche to Test Whether New Drug Can Prevent Alzheimer's Disease

Roche Holding AG plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, its latest investment in one of the most failure-prone areas of drugmaking. The new late-stage study will focus on people who are at risk of cognitive decline, Roche said in a statement late Sunday. The goal would be to slow down the emergence of symptoms, or prevent them entirely.

DZ BANK AG Reaffirms Their Buy Rating on Roche Holding AG (RHHVF)
DZ BANK AG Reaffirms Their Buy Rating on Roche Holding AG (RHHVF)

Business Insider

time3 days ago

  • Business
  • Business Insider

DZ BANK AG Reaffirms Their Buy Rating on Roche Holding AG (RHHVF)

DZ BANK AG analyst Elmar Kraus maintained a Buy rating on Roche Holding AG on July 25. The company's shares closed last Friday at $330.52. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Kraus covers the Healthcare sector, focusing on stocks such as Novartis AG, AstraZeneca, and Koninklijke Philips N.V.. According to TipRanks, Kraus has an average return of 8.1% and a 68.85% success rate on recommended stocks. The word on The Street in general, suggests a Hold analyst consensus rating for Roche Holding AG with a $353.24 average price target, which is a 6.87% upside from current levels. In a report released on July 25, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a CHF296.00 price target. Based on Roche Holding AG's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $30.65 billion and a net profit of $2.02 billion. In comparison, last year the company earned a revenue of $28.94 billion and had a net profit of $4.36 billion

Deutsche Bank Reaffirms Their Sell Rating on Roche Holding AG (RHHVF)
Deutsche Bank Reaffirms Their Sell Rating on Roche Holding AG (RHHVF)

Globe and Mail

time6 days ago

  • Business
  • Globe and Mail

Deutsche Bank Reaffirms Their Sell Rating on Roche Holding AG (RHHVF)

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Sell rating on Roche Holding AG, with a price target of CHF235.00. The company's shares closed yesterday at $321.46. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Papadakis is a 4-star analyst with an average return of 3.5% and a 51.43% success rate. Papadakis covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Novartis AG, and AstraZeneca. In addition to Deutsche Bank , Roche Holding AG also received a Sell from J.P. Morgan's Richard Vosser in a report issued yesterday. However, on July 17, Berenberg Bank maintained a Hold rating on Roche Holding AG (Other OTC: RHHVF). The company has a one-year high of $354.19 and a one-year low of $269.80. Currently, Roche Holding AG has an average volume of 11.61K.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store